Smoking Increases Side Effect, Recurrence Risk in Prostate Cancer
the ONA take:
The fact that smoking contributes to a poor prognosis in many diseases and conditions is well-known. A recent study from Memorial Sloan Kettering Cancer Center in New York City confirmed the effects on smoking on patients with prostate cancer.
Those who smoke have increased risks of experiencing treatment-related side effects and cancer recurrences, or even dying from the disease. These researchers studied 2,358 patients who underwent external beam radiotherapy for prostate cancer between 1988 and 2005, of which 2,156 had a history of smoking.
Risk of cancer relapse was 40% higher and risk of metastasis and cancer-related death was more than 2-times higher in patients who were current smokers compared with patients who were never smokers.
Current and former smokers also had a higher likelihood of experiencing side effects, such as urinary toxicity, related to radiotherapy. "Less optimal tumor control outcomes among smokers could possibly be explained by the influence of less oxygen concentration within the treated tumors among smokers, which is known to lead to less sensitivity of the cells being killed off by radiation treatments," the researchers noted.
Recent study confirmed the effects on smoking on patients with prostate cancer.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|